SCHEMBL2914627

SCHEMBL2914627

O=C(O)Cc1cccc(N2CCC3(CC2)C(=O)N(CC2CCCC2)C(=O)N3Cc2ccc(C(F)(F)F)cc2C(F)(F)F)c1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 2/20 0.37
HSD11B1 P28845 1/20 0.36
FFAR4 Q5NUL3 3/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
UBE2M P61081 2/20 0.36
DCUN1D1 Q96GG9 2/20 0.36
CHRM4 P08173 1/20 0.36
HRH1 P35367 1/20 0.36
CCR3 P51677 1/20 0.36
KCNH2 Q12809 1/20 0.36
ITGB3 P05106 2/20 0.35
ITGA2B P08514 2/20 0.35
OPRM1 P35372 2/20 0.35
OPRL1 P41146 2/20 0.35
POLB P06746 2/20 0.34
OPRK1 P41145 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
SIGMAR1 Q99720 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2914958 0.90 ITGB3 (0.41) TACR1HSD11B1LMNAKMT2ACHRM4
SCHEMBL2909717 0.89 ITGB3 (0.41) TACR1HSD11B1LMNAKMT2ACHRM4
SCHEMBL2910510 0.86 SIGMAR1 (0.38) TACR1HSD11B1FFAR4LMNAKMT2A
SCHEMBL2915435 0.84 SIGMAR1 (0.38) TACR1FFAR4LMNAKMT2AHRH1
SCHEMBL4124559 0.83 CHRM4 (0.39) FFAR4KMT2ACHRM4HRH1CCR3
SCHEMBL2918305 0.82 CHRM4 (0.45) FFAR4CHRM4HRH1CCR3KCNH2
SCHEMBL4120112 0.81 CHRM4 (0.45) FFAR4CHRM4HRH1CCR3KCNH2
SCHEMBL13212510 0.81 OPRL1 (0.41) TACR1HSD11B1CHRM4KCNH2OPRM1
SCHEMBL13212985 0.81 ITGB3 (0.42) TACR1FFAR4HRH1CCR3KCNH2
SCHEMBL2914632 0.81 TACR1 (0.34) TACR1HSD11B1CHRM4HRH1CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US claimed
EP-1979355-B1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2010-08-18 EP disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed
WO-2007087448-A1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS PPARD, PPARG, PPARA TACR1 657/4885HSD11B1 83/4885FFAR4 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.